Journal
EUROPEAN HEART JOURNAL
Volume 33, Issue 2, Pages 165-U148Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehr239
Keywords
Pharmacogenetics; Single-nucleotide polymorphism; Drug therapy; Drug response; Cardiovascular disease; Systematic review
Categories
Funding
- European Union [HEALTH-F2-2009-223004]
- Interuniversity Cardiology Institute of the Netherlands (ICIN)
- Durrer Center for Cardiogenetic Research both Institutes of the Netherlands Royal Academy of Arts and Sciences (KNAW)
- Netherlands Heart Foundation [2001D032]
- Center for Medical Systems Biology (CMSB)
- centre of excellence approved by the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NWO)
- Netherlands Consortium for Healthy Ageing (NCHA)
Ask authors/readers for more resources
Pharmacogenetics is the search for heritable genetic polymorphisms that influence responses to drug therapy. The most important application of pharmacogenetics is to guide choosing agents with the greatest potential of efficacy and smallest risk of adverse drug reactions. Many studies focusing on drug-gene interactions have been published in recent years, some of which led to adaptation of FDA recommendations, indicating that we are on the verge of the clinical application of genetic information in drug therapy. This systematic review provides a comprehensive overview of the current knowledge on pharmacogenetics of all major drug classes currently used in the treatment of cardiovascular diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
